Phase 4 Uveitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 6 and 17 years old (at the time of giving consent to join)
- You have a non-infectious form of uveitis (inflammation inside the eye that is not caused by infection) affecting the middle or back of the eye, and it has come back at least once a year
- Your uveitis in the affected eye has not been well controlled by standard treatments, either because of unpleasant side effects or because the treatments haven't worked well enough
- You have been taking steroid tablets or other systemic (whole-body) treatments for at least 3 months during the past 12 months
Who may not be able to join:
- You have had surgery inside the affected eye within the last 90 days before your screening appointment
- You have a known allergy or sensitivity to the drug used in this trial (called fluocinolone acetonide, or ILUVIEN®) or any of its ingredients
- You have a history of glaucoma (a condition causing pressure build-up in the eye) or high eye pressure in the affected eye, unless you have already had a specific surgical procedure to lower that pressure at least 90 days before screening and your eye pressure is now stable and in the normal range (confirm with trial site)
- Your eye pressure has been higher than 25 mmHg, or has needed extra treatment, surgery, or hospitalisation, within the 4 weeks before the start of the trial, and the study doctor feels this would put you at unacceptable risk
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 353 (0) 1 553 0215
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.; Rate of cataract formation and Rate of IOP elevation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.